This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F14%3A10283673%21RIV15-MSM-11150___/
n3http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F14%3A10283673%21RIV15-MSM-11150___
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01
dcterms:description
The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs) started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many of driver gene aberrations are inversions or translocations and thus require FISH analysis, each requires a certain amount of tumor cells from an already limited amount. In this respect new genetic test systems have been introduced such as next generation sequencing, which enables to detect multiple mutations at once, as well as amplifications and fusion genes. As soon as these methods are validated for routine use this will enable the analysis of multiple genetic changes simultaneously. In this review we focus on genetic changes in NSCLC, resistance to new target therapies, and also to requirements for a meaningful evaluation of lung cancer tissue and cells. The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs) started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many of driver gene aberrations are inversions or translocations and thus require FISH analysis, each requires a certain amount of tumor cells from an already limited amount. In this respect new genetic test systems have been introduced such as next generation sequencing, which enables to detect multiple mutations at once, as well as amplifications and fusion genes. As soon as these methods are validated for routine use this will enable the analysis of multiple genetic changes simultaneously. In this review we focus on genetic changes in NSCLC, resistance to new target therapies, and also to requirements for a meaningful evaluation of lung cancer tissue and cells.
dcterms:title
Molecular testing in lung cancer in the era of precision medicine Molecular testing in lung cancer in the era of precision medicine
skos:prefLabel
Molecular testing in lung cancer in the era of precision medicine Molecular testing in lung cancer in the era of precision medicine
skos:notation
RIV/00216208:11150/14:10283673!RIV15-MSM-11150___
n4:aktivita
n19:I
n4:aktivity
I
n4:cisloPeriodika
5
n4:dodaniDat
n8:2015
n4:domaciTvurceVysledku
n16:1141147
n4:druhVysledku
n17:J
n4:duvernostUdaju
n14:S
n4:entitaPredkladatele
n18:predkladatel
n4:idSjednocenehoVysledku
30308
n4:idVysledku
RIV/00216208:11150/14:10283673
n4:jazykVysledku
n5:eng
n4:klicovaSlova
requirements; molecular testing; lung cancer
n4:klicoveSlovo
n11:requirements n11:lung%20cancer n11:molecular%20testing
n4:kodStatuVydavatele
IN - Indická republika
n4:kontrolniKodProRIV
[AC3D56D727FF]
n4:nazevZdroje
TLCR Translational lung cancer research
n4:obor
n7:FP
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
4
n4:rokUplatneniVysledku
n8:2014
n4:svazekPeriodika
3
n4:tvurceVysledku
Olszewski, Wlodzimierz Tímár, Jozsef Ryška, Aleš Popper, Helmut H.
s:issn
2218-6751
s:numberOfPages
10
n13:doi
10.3978/j.issn.2218-6751.2014.10.01
n3:organizacniJednotka
11150